Skip to content

COVID-19 Critical Care Consortium Observational Study Incorporating the Extracorporeal Membrane Oxygenation for 2019 Novel Coronavirus Acute Respiratory Disease (ECMOCARD)

COVID-19 Critical Care Consortium Observational Study Incorporating the Extracorporeal Membrane Oxygenation for 2019 Novel Coronavirus Acute Respiratory Disease (ECMOCARD)

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ANZCTR
Registry ID
ACTRN12620000421932
Acronym
COVID-19 CCC inc ECMOCARD
Enrollment
2141
Registered
2020-03-30
Start date
2020-03-05
Completion date
2020-12-31
Last updated
2020-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

We hypothesize that a significant percentage of patients with suspected or confirmed COVID-19 infection will require admission to the intensive care unit, mechanical ventilation and ECMO for refractory hypoxemia., In addition, it is hypothesized that a substantial proportion of patients will also present with concurrent coagulation disorders and thrombosis. Objectives: To describe clinical features; severity of pulmonary dysfunction; incidence of ICU admission and use of mechanical ventilation, coagulatory and thrombotic derangement, and ECMO technical characteristics; duration of ECMO; complications; and survival of patients with suspected or confirmed COVID-19.

Interventions

In patients with suspected or confirmed 2019-nCoV who require admission to the intensive care unit mechanical ventilation and extracorporeal membrane oxygenation (ECMO). It is expected that this study will not require individual patient consent. This study is in effect a large-scale clinical audit during a global health emergency, as all data is already recorded as part of routine clinical care, therefore justifying participant enrolment using a waiver of consent. Retrospective data will be sour

In patients with suspected or confirmed 2019-nCoV who require admission to the intensive care unit mechanical ventilation and extracorporeal membrane oxygenation (ECMO). It is expected that this study will not require individual patient consent. This study is in effect a large-scale clinical audit during a global health emergency, as all data is already recorded as part of routine clinical care, therefore justifying participant enrolment using a waiver of consent. Retrospective data will be sourced from all collaborating hospitals across Australia from January 2020 to March 2020. Whereas, international hospitals will provide their retrospective data between January 2019 and march 2020. Prospective data will be collected in Australian and International hospitals until completion of COVID-19 global epidemic, as judged by the World Health Organization. The total duration of observation per participant will be until hospital discharge or 28 days post intensive care unit admission, whichever comes later. The study will combine prospective observation, and retrospective observations sourced from clinical charts.

Sponsors

Extracorporeal Life Support Organisation
Lead SponsorCharities/Societies/Foundations

Eligibility

Sex/Gender
All
Healthy volunteers
No

Inclusion criteria

1. Clinical suspicion or laboratory-confirmed COVID-19 infection by real-time PCR and/or next-generation sequencing 2. Admission to an intensive care unit

Exclusion criteria

1. Patients treated with mechanical ventilation for other concomitant causes. 2. Patients treated with ECMO for other concomitant causes

Outcome results

None listed

Source: ANZCTR · Data processed: Feb 18, 2026